Elite Pharmaceuticals Launches Generic Methadone Tablets, Tapping into $22M Market
ELTP sits 30% above its 52-week low of $0.27.
Summary
Elite Pharmaceuticals announced the commercial launch of its generic methadone hydrochloride 5 mg and 10 mg tablets, entering a market with estimated annual retail sales of $22 million.
Key Events · Product Development and Regulatory · ELTP
-
Commercial Product Launch
Elite Pharmaceuticals, Inc. has commercially launched its generic version of methadone hydrochloride 5 mg and 10 mg tablets under the Elite Laboratories, Inc. label.
-
Market Opportunity
Based on IQVIA data, the brand and generic products in this category had estimated annual retail sales of approximately $22 million in 2025.
-
Strategic Growth
This launch aligns with Elite's focus on developing and distributing niche generic products, contributing to its ongoing efforts to expand its revenue base following a recent financial turnaround.
Analysis · ELTP · Life Sciences
Elite Pharmaceuticals' commercial launch of generic methadone hydrochloride tablets represents a positive step in expanding its product portfolio and revenue streams. This new product targets an existing market with annual retail sales of approximately $22 million, providing a tangible growth opportunity for the company. Coming after a period of significant financial turnaround, this launch reinforces Elite's strategy in niche generic products and could contribute to sustained revenue growth and profitability.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELTP was trading at $0.35 on OTC in the Life Sciences sector, with a market capitalization of approximately $402.1M. The 52-week trading range was $0.27 to $0.82. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.